AbbVie Inc. (ABBV) — Analyst outlook / Analyst consensus target is. Based on 40 analyst ratings, the consensus is bullish — 27 Buy, 12 Hold, 1 Sell.
The consensus price target is $256.15 (low: $223.00, high: $299.00), representing an upside of 21.8% from the current price $210.32.
Analysts estimate Earnings Per Share (EPS) of $10.08 and revenue of $56.04B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $2.40 vs est $10.08 (missed -76.2%). 2025: actual $2.38 vs est $9.94 (missed -76.1%). Analyst accuracy: 0%.
ABBV Stock — 12-Month Price Forecast
$256.15
▲ +21.79% Upside
Average Price Target
Based on 40 Wall Street analysts offering 12-month price targets for AbbVie Inc., the average price target is $256.15, with a high forecast of $299.00, and a low forecast of $223.00.
The average price target represents a +21.79% change from the last price of $210.32.
Highest Price Target
$299.00
Average Price Target
$256.15
Lowest Price Target
$223.00
ABBV Analyst Ratings
Buy
Based on 40 analysts giving stock ratings to AbbVie Inc. in the past 3 months
EPS Estimates — ABBV
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $2.40
vs Est $10.08
▼ 320.1% off
2025
Actual $2.38
vs Est $9.94
▼ 317.6% off
Profitability Outlook
Company is profitable with solid earnings. EPS trend is declining. Analysts forecast meaningful EPS growth ahead.
Revenue Estimates — ABBV
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $56.334B
vs Est $56.042B
▲ 0.5% off
2025
Actual $61.160B
vs Est $60.965B
▲ 0.3% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
